Diagnostics

Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, and Parkview Health, one of the fastest growing health systems in the Midwest, announce a strategic agreement for Labcorp to acquire select assets of the health system’s outreach laboratory services that provides high-quality testing across Indiana and northwest Ohio. Once finalized, the transaction […]

Align Capital Partners’ (“ACP”) drug and alcohol testing solutions provider Premier Biotech (“Premier” or the “Company”) has acquired National Test Systems (“NTS”), a leading provider of rapid point-of-care diagnostic drug screening supplies and services throughout the United States. NTS serves over 1,500 facilities throughout the United States, primarily in Government and Behavioral Health end markets

Fibronostics, a global leader in non-invasive diagnostics for metabolic and liver diseases, announces the completion of its acquisition of Stone Clinical Laboratories, LLC, a leading provider of advanced laboratory services in the United States. This strategic acquisition strengthens Fibronostics’ research and development position and reinforces its commitment to innovation in metabolic dysfunction-associated steatohepatitis (MASH) and

ARCHIMED Diagnostics – the Diagnostics team of global private equity healthcare specialist ARCHIMED – has closed its carve-out of Freemont, California-based ARK Diagnostics from listed South Korean specialty chemical company, Soulbrain Holdings. ARK is ARCHIMED Diagnostics’ third investment in 2025. The transaction gives ARK an enterprise value of $428 million. ARK is a global leader